ArticleMedical hypotheses2020
A putative role for the tobacco mosaic virus in smokers' resistance to COVID-19.
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis.Addiction science & clinical practice · 2022Pooled it
- Smoking as a Risk or Protective Factor in Developing and Severity of COVID-19?Journal of acute medicine · 2023Article
- Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research.The Lancet. Respiratory medicine · 2022Review
- The Association of Opioid Use Disorder and COVID-19, a Longitudinal Study.International journal of preventive medicine · 2022Article
- Microbiology of the American Smokeless Tobacco.Applied microbiology and biotechnology · 2021Review
- Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- A roadmap from unknowns to knowns: Advancing our understanding of the microbiomes of commercially available tobacco products.Applied microbiology and biotechnology · 2021Review
- Considerations on the article De Bernardis, E., & Busà, L. (2020). A putative role for the tobacco mosaic virus in smokers' resistance to COVID-19 Medical Hypotheses, 110153.Medical hypotheses · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports from various countries suggest that tobacco smoking might protect from SARS-CoV-2 infection, since the prevalence of smoking in COVID-19 hospitalized patients is lower than in the respective general population. Apart from nicotine or other chemicals contained in tobacco smoke, we propose that a single-stranded RNA virus that infects tobacco leaves, tobacco mosaic virus (TMV), might be implicated in this effect. TMV, though non-pathogenic, is found in smokers' airways, and stimulates adaptive and innate immunity, with release of specific antibodies and interferons. The latter may have preventive and/or therapeutic effects against COVID-19. If confirmed by epidemiological and interventional studies, this might lead to the use of TMV as an immunological adjuvant against SARS-CoV-2 infection and COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.